The theses of the study confirming the antioxidant properties of Mexidol® are accepted by the European Society of Cardiology (ESC)

The results of the study of the effect of Mexidol® (2-ethyl-6-methyl-3-hydroxypyridine succinate) on oxidative stress in patients with decompensated heart failure and cognitive impairment are published on the website of the European Society of Cardiology, https://www.escardio.org/Search/?q=Mexidol&filters:content_type=ESC365%20Presentation. The purpose of the study was to evaluate the effect of Mexidol® on the level of oxidative stress markers (malondialdehyde*, superoxide dismutase**, glutathione peroxidase***), plasma antioxidant activity in patients with decompensated heart failure and cognitive impairment. Oxidative stress markers were investigated at the beginning of therapy and after its completion. Patients treated with Mexidol® showed a significant decrease in the level of malondialdehyde - by 20.77% (p=0.02) and a significant increase - by 20.68% - in the level of glutathione peroxidase (p=0.04), as well as a tendency to increase the level of superoxide dismutase by 43.43% and plasma antioxidant activity by 42.69%.

Thus, the study showed a marked antioxidant effect of Mexidol® in patients with decompensated heart failure and cognitive impairment.

Note:

*Malondialdehyde is an endogenous aldehyde, which is a clinical and laboratory oxidative stress marker used to predict and control the treatment of a wide range of diseases, including heart failure.

**Superoxide dismutase is one of the main intracellular antioxidant protection enzymes catalyzing the decomposition of superoxide into oxygen and hydrogen peroxide. It takes an important part in the antioxidant protection of almost all cells.

***Glutathione peroxidase is one of the main intracellular antioxidant enzymes catalyzing restoration of lipid hydroperoxides into alcohols and restoration of hydrogen peroxide to the state of water.


Antioxidants used against viral infections

Escaping coronavirus infection is a question that arises with the awareness of the gravity of the global situation. These are social distance, hand hygiene, and immune system reinforcement that specialists can so far advise. Treatment of pneumonia that develops against the background of COVID-19 infection allows of various clinical and pharmacological approaches, including experimental ones.

One of the directions of respiratory viral infections control may be maintenance of metabolic processes in cells. Using antioxidants, doctors increase the cells protection against oxidative stress and help the cells to resist not only infections, but also heart disease, brain disease and even aging process. Science knows more than 400 types of antioxidants: from ascorbic acid to such antioxidants as Mexidol®, which is included in 38 major standards of medical care in Russia.


Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Mexidol in Prolonged Sequential Therapy of Patients in the Acute and Early Recovery Stages of Hemispheric Stroke (the EPICA study)

Author:
L. V. Stakhovskaya1, N. A. Shamalov1, D. R. Khasanova2, E. V. Mel’nikova3, A. S. Agaf’ina4, K. V. Golikov5, E. I. Bogdanov6, A. A. Yakupova6, L. V. Roshkovskaya7, L. V. Lukinykh8, T. M. Lokshtanova9, I. E. Poverennova10, and L. A. Shchepankevich11

1 Research Institute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia; e-mail: lstakh@mail.ru.

2 Interregional Clinical Diagnostic Center, Kazan, Russia.

3 St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.

4 St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.

5 St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.

6 Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.

7 Nikolaevskaya Hospital, St. Petersburg, Russia.

8 Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.

9 Pirogov City Clinical Hospital No. 1, Samara, Russia.

10 Seredavin Samara Regional Clinical Hospital, Samara, Russia.

11 Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Summary:
Objectives. To assess the effi cacy and safety of prolonged sequential therapy with Mexidol in patients with hemispheric ischemic stroke (IS) in the acute and early recovery phases. Materials and methods. A randomized, double-blind, multicenter, placebo-controlled, parallel-group study included 151 patients (62 men and 89 women) was performed in which 150 patients (62 men and 88 women) aged 40–79 years were randomized. Simple randomization was used to defi ne two groups: patients of group 1 received Mexidol therapy at a dose of 500 mg/day by intravenous infusion for 10 days followed by oral doses of 1 tablet (125 mg) three times a day for eight weeks. Patients of group 2 received placebo by the same protocol. The duration of involvement in the trial was 67–71 days. Results. At the end of treatment, mean scores on the modified Rankin scale (mRS) were lower in group 1 than group 2 (p = 0.04). Decreases in mean mRS scores (at visits 1–5) were more marked in group 1 (p = 0.023). The proportion of patients achieving recovery corresponding to 0–2 points on the mRS (at visit 5) was signifi cantly greater in group 1 (p = 0.039). Testing on the National Institutes of Health Stroke Scale at visit 5 gave a signifi cantly lower score in group 1 (p = 0.035). Decreases in scores on the National Institutes of Health Stroke Scale at the end of treatment relative to the baseline level in patients with diabetes mellitus were more marked in group 1 (p = 0.038). In group 1, the total population and the subpopulation of patients with diabetes mellitus showed more marked improvements in quality of life, which was apparent by visit 2. The proportion of patients without diffi culty mobilizing was signifi cantly greater in group 1 (p = 0.022). There were no signifi cant differences in the frequencies of adverse events in patients of the two groups. Conclusions. Use of Mexidol in the acute and early recovery phases of IS is recommended. Keywords: acute cerebrovascular accident, Mexidol, ethylmethylhydroxypyridine succinate, effi cacy and safety, ischemic stroke, acute phase, early recovery phase, EPICA.


The efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia

This article is in "Library" section.

Author:

Yu.V. ABRAMENKO
Tver State Medical University, Tver, Russia

Read more.


Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study

This article is in "Library" section.

Author:

T.A. VORONINA

FSBI «Zakusov Institute of Pharmacology», Moscow

Read more.


The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia

This article is in "Library" section.

Author:

V.V. BURDAKOV, D.V. KRASNYKH
Orenburg State Medical University, Ministry of Health of Russia, Orenburg, Russia

Read more.


The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging

This article is in "Library" section.

Author:

YU.I. KIROVA1, F.M. SHAKOVA1, E.L. GERMANOVA1, G.A. ROMANOVA1, T.A. VORONINA2

1 Institute of General Pathology and Pathophysiology, Moscow, Russia;

2 Zakusov Research Institute of Pharmacology, Moscow, Russia

Read more.


The efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia

Author:
Yu.V. ABRAMENKO
Tver State Medical University, Tver, Russia

Summary:
Objective. To study the efficacy and safety of mexidol’s intravenous injections (500 mg once a day) for 14 days, followed by oral administration of mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days, in treatment of chronic cerebral ischemia (CCI) in patients with hypertension and atherosclerosis of the brachiocephalic arteries. Material and methods. The observation program included 60 patients with an established diagnosis of CCI confirmed by neuroimaging methods. Patients of the main group (n=26) received mexidol along with basic therapy, patients of the comparison group (n=26) received only basic therapy. Results and conclusion. The results of the experience show the high efficacy and safety of sequential therapy (parenteral therapy followed by tablets of mexidol FORTE 250). The treatment improves emotional and cognitive status, decreases static-motor disorders and severity of subjective neurological symptoms. High adherence of patients to the therapy is shown.
Keywords: chronic cerebral ischemia, arterial hypertension, atherosclerosis of the brachiocephalic arteries, mexidol, static-motor
disorders, cognitive impairment.


The efficacy of ethylmethylhydroxypyridine in the rehabilitation treatment of poststroke patients

This article is in "Library" section.

Author:

O.V. M.V. ZHURAVLEVA1,2, A.B. PROKOFIEV1,2, V.V. ARKHIPOV1, S.YU. SEREBROVA1,2, G.I. GORODETSKAY1,2, O.A. DEMIDOVA1

1 Research center for examination of medical devices, Moscow, Russia

2 Sechenov First Moscow state medical University (Sechenov University), Moscow, Russia

Read more.


Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study

Author:
T.A. VORONINA

FSBI «Zakusov Institute of Pharmacology», Moscow

Summary:
Objective. To study an effect of mexidol on the life expectancy, weight, seizure response thresholds, and impaired cognitive and
motor functions during aging in male Wistar rats. Material and methods. In a long-term experiment, male Wistar rats, aged 3—26 months, were assessed for impaired cognitive functions (passive avoidance conditioned reflex test), convulsive threshold (test with pentylenetetrazole), motor deficits (tests of rotating rod and pulling on the crossbar), and life expectancy. The rats received mexidol in the form of 0,15% solution, which replaced drinking water, during two 2 month courses at the age of 18—20 and 22—24 month. A dose of mexidol consumed by the rat was 40-75 mg/kg/day. Results. In old male Wistar rats, the long-term treatment with mexidol increases the life expectancy, improves learning, preservation and reproduction of the memory trace in the passive avoidance conditioned reflex test, increases the convulsive threshold and improves muscle tone and coordination of movements that are impaired during aging. Conclusion. Mexidol increases the threshold of convulsive reaction, restores cognitive and neurological deficits that occur during aging in male Wistar rats and increases the by its ability to influence mitochondriogenesis and antioxidant properties.
Keywords: aging, mexidol, life expectancy, memory impairment, neurological deficit, convulsive threshold.